Talk:MTORC1

Wiki Education Foundation-supported course assignment
This article was the subject of a Wiki Education Foundation-supported course assignment, between 24 August 2021 and 10 December 2021. Further details are available on the course page. Student editor(s): GutierrezEmily, Mxt15, Tanishabph. Peer reviewers: Mxt15.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 00:22, 18 January 2022 (UTC)

Class Project
Hi mTOR editors, this is Bobby, a student in a Signal Transduction class at Saint Louis University. Each student is allowed to pick a topic that they found exciting as well as a topic they felt could expand the current wikipedia knowledge on. This article, along with mTOR and mTORC2 are going to be what I am going to be editing for the rest of the semester. If you have any help or input or advice, don't hesitate to leave a comment on my talk page. I am planning on, for the editing, reading upwards of twenty review articles (and perhaps a couple primary articles) about mTOR and its signaling within the cell and using that information to help (hopefully) add to the current knowledge about this protein (these proteins) already supplied on Wikipedia. This is just to help give a heads up that I am working on this. Thanks,Flemingrjf (talk) 03:22, 18 February 2013 (UTC)

Comments from Gpruett2
Here are my comments for this article:


 * The structure and the writing are very sound, although, I have made a few minor edits in order to make sentences a little more straightforward. You can revert my changes if you feel like it.
 * Your sourcing is also very well done. You have it formatted correctly; however, there is one big issue that I found.  A large chunk of information under Mitogens is not cited.  This needs to be fixed as soon as possible.
 * In regards to the information directly under Insulin, is 12 the correct source for it? I ask because I checked out the article and cannot find mention of serine residue 939, serine residue 981, or threonine residue 1462.
 * In the first sentence directly under S6K, if feel that the its in its serine residue is too vague. I cannot tell if it is referring to eIF4B or S6K.
 * As far as adding further sections, I would suggest including a history/discovery section (if possible) and a clinical importance section.

Overall, the article looks, reads, and flows nicely. Keep up the good work. Gpruett2 (talk) 04:41, 4 April 2013 (UTC)


 * Please note the disambiguation box at the top. The links need to be checked and fixed.
 * Terrific improvement on this article. Biolprof (talk) 02:57, 14 April 2013 (UTC)

Response to Gpruett2 and Biolprof

 * Those changes were appreciated and fine with me!


 * I left out a lot of sources for this, because I assumed it was "common knowledge" for the people reading such articles. However, I added some references for this pathway.


 * I added the original article that this came from.


 * I clarified this problem. S6K phosphorylates the serine residue on eIF4B. Stating what residue might not be necessary, but if someone feels like it should be taken down to reduce "clutter" they may feel free.


 * I added a history/discovery section to the main mTOR page during my last edit. The focus of my second edit is the addition of a clinical importance section as will become evident.

Flemingrjf (talk) 04:28, 16 April 2013 (UTC)
 * Biolprof - the disambiguity of the links has been taken care of

Comments from Jnims
Great job so far! I've included my suggestions for improvement below as part of our Assignment 7. You'll notice that some are the same as for your main article (mTOR).

Lead section
 * Add "itself" at the end of this phrase to underscore the presence of mTOR in the complex: "mTOR Complex 1 (mTORC1) is composed of mTOR."
 * Thus, the entire sentence would read, "mTOR Complex 1 (mTORC1) is composed of mTOR itself, regulatory-associated protein of mTOR (Raptor), mammalian lethal with SEC13 protein 8 (MLST8) and the recently identified partners PRAS40 and DEPTOR."
 * Done.
 * The meaning of "partners" is unclear; consider adding more information about what makes them partners: "and the recently identified partners PRAS40 and DEPTOR." Also, I don't see any mention of those two proteins in the two sources you cited (#s 15 and 16). Am I missing something (entirely possible!), or is there a better source that identifies those molecules by name?
 * Yeah I added better sources for that. Those ones were not added by me.
 * The wording in this sentence could be improved: "This complex is characterized by the classic features of mTOR by functioning as a nutrient/energy/redox sensor and controlling protein synthesis."
 * Suggestion: "This complex embodies the classic functions of mTOR, namely as a nutrient/energy/redox sensor and controller of protein synthesis."
 * I did what you said. It sounds better, thanks.
 * A PyMOL representation of the mTORC1 structure would be helpful.
 * This is the only picture that I haven't yet done. I will hopefully get this up by the tenth. The problem with drawing one structure is that there is currently no consensus of what the structure of mTORC1 should be just yet and different articles have different structures.

Upstream signaling section
 * This sentence needs rewording for clarity: "This allows mTORC1 to physically interact with Rheb and thus endosomes and lysosomes are where Rheb will activate mTORC1."
 * Yeah that was a bad sentence. Thanks I redid it.
 * Ditto this: "When amino acids are introduced to a deprived cell, the presence of amino acids causes Rag GTPase heterodimers to switch to their active conformation."
 * Suggestion: "The presence of amino acids introduced to a deprived cell cause Rag GTPase heterodimers to switch to their active conformation."
 * Wrote what you said. Sounds better. Thanks.
 * An illustration of the pathways would be helpful. For instance, I added a generic illustration of the signaling pathway involved in my article's subject here.
 * Illustrations were the main thing that my article needed. I added all except the one showing the structure of the complex.
 * The latter part of this sentence needs rewording for clarity: "Mitogens, like insulin like growth factor 1 (IGF1), can activate the MAPK/ERK pathway, which can control the TSC1/TSC2 complex as well as directly have the same downstream role of mTORC1."
 * Reworded it. Thanks.
 * Substitute "found" for "studied" in this sentence: " It has been studied that the AMPK is required to first phosphorylate residue 1345 before GSK3 beta can phosphorylate its target serine residues."
 * Did so. Not sure why I put studied.

Jnims (talk) 01:12, 23 April 2013 (UTC)

Peer Review comments from MChapman5
MChapman5 (talk) 07:07, 30 April 2013 (UTC)
 * A few more citations in the "Amino acids" section would be nice.
 * I added two more. I am not sure why that section had as few citations as it did.
 * How about provided a picture or image depicting some of the pathways you discuss in the "growth factors" section? It may be nice to see a visual representation of what the mTORC1 is acting on without having to go to another article.
 * Added a picture. The best thing I could do for the article at this point in its development.
 * Could you add a chart or a table to summarize the date you have in the "Downstream signaling section"? This piece of the page is very text heavy and dense, and it may be nice to be able to glimpse the general overview via a table or some other format.
 * Added a picture instead.
 * Should Rapamycin have its own section under "First Generation Inhibitors"? I say this because you provided a lot of information on this drug in your presentation, and you also demonstrated its importance in the pathway. I think this gives it enough criteria to have its own section on the causes and effects it produces for mTORC1.
 * I tried to present it at the beginning to introduce the Target of Rapamycin, and then mTOR. Right now, the first generation inhibitors are still being developed. In the not to distant future, I think alot of information can be provided to this section, enough to make there be perhaps two separate sections: one for rapamycin and the other for the other first generation inhibitors.
 * The last part of the "Second generation inhibitors" says that there are over 1,300 clinical trials underway. Should this be given its own section? Can you extrapolate on any data/experiments for these trials?
 * I have not been able to get access to many of the articles about the second generation inhibitors, or the inhibitors for mTORC1 in general. I don't think the university has access to these specialized journals regarding drug developments.
 * Very good article! You've done an amazing job contributing to Wikipedia.
 * Thank you Matt!

Peer Review: BreCaitlin
BreCaitlin (talk) 17:19, 1 May 2013 (UTC)
 * Maybe reverse the order of the first two sentences in the Amino acids section
 * Yeah that sounds much better. Thanks.
 * Citations look good
 * Thank you.
 * Technical in a good way, easy to understand
 * I hopefully didn't lose anybody in the details.
 * Could use a picture or two
 * Added pictures. Probably the best spent time I could have done for the article at this point.

Comments from Jnims
Thanks for taking my suggestions, I hope you found them helpful. Your article looks very good, overall. Let's start with the things I particularly enjoyed/appreciated:

Good stuff

 * A wealth of informative content
 * Lots of excellent citations
 * Good images
 * Very nice organization
 * Thank you!

And here are some suggestions for improvement:

Suggested improvments
Activation at the lysosome Upstream signaling Downstream signaling
 * Consider adding examples of the variables mentioned in this sentence, even just two or three: "Almost all of these variables for protein synthesis affect mTORC1 activation by interacting with the TSC1/TSC2 protein complex."
 * Yeah this was a transition from the above paragraph, but that is hard to get across due to the big physical space on the screen between the two. I'll figure something out for how to fix this. Thanks.
 * This sentence is a little confusing: "This allows mTORC1 to physically interact with Rheb and thus endosomes and lysosomes are where Rheb will activate mTORC1"
 * I agree. Changed it.
 * Consider adding an image of the Akt and MAP/ERK signaling pathways. You could even use the same one I did: http://en.wikipedia.org/wiki/File:MAPK-pathway-mammalian.png
 * And here's one that includes Akt and mentions mTOR explicitly: http://en.wikipedia.org/wiki/File:MTOR-pathway-v1.7.svg
 * I did not include this figure, but I did see it. To me, it just seems ever more confusing, and nothing was gained by it. If anything, it just intimidates the casual viewer of the page.
 * Consider adding at least one more sentence at the beginning, so the section intro doesn't look so empty.
 * That sounds good. Did that.
 * This sentence, especially the first half, is awkward: "As a result, mTORC1 signaling was focused on and techniques used to inhibit its activity in C. elegans, fruitflies, and mice significantly increased their lifespans relative to the control organisms for the respective species."
 * Changed that sentence.
 * Also, be sure to italicize Latin (genus/species) and gene names.
 * Alright, thanks for the technical input. Attention to details is always a good thing.

Best of luck! Jnims (talk) 19:53, 8 May 2013 (UTC)

K20 reading level
mTOR Complex 1 (mTORC1) is composed of the mTOR protein complex, regulatory-associated protein of mTOR (commonly known as raptor), mammalian lethal with SEC13 protein 8 (MLST8), PRAS40 and DEPTOR.

Come on, now. That requires a K20 educational attainment level merely to parse correctly. &mdash; MaxEnt 19:41, 28 December 2022 (UTC)